Hepatitis B Virus DNA Level as Predictor of Response to Therapy with Interferon-alpha-2b (PDferon) in Chronic Hepatitis B Infection

AUTHORS

Seyed Moayed Alavian 1 , * , Seyed Mohammad Miri 1 , Mohammad Javad Behzadnia 1

1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah Medical Sciences University, Tehran, IR Iran

How to Cite: Alavian S M, Miri S M, Behzadnia M J. Hepatitis B Virus DNA Level as Predictor of Response to Therapy with Interferon-alpha-2b (PDferon) in Chronic Hepatitis B Infection, Arch Clin Infect Dis. Online ahead of Print ; 6(1):5-17.

ARTICLE INFORMATION

Archives of Clinical Infectious Diseases: 6 (1); 5-17
Article Type: Research Article

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: To evaluate the strength of association and to determine the best prediction of response in terms of sensitivity and specificity among quantitative baseline HBV-DNA levels in blood serum in patients with chronic hepatitis B (CHB) infection who treated with interferon-alpha-2b.

Patients and Methods: Totally, 78 CHB patients with serum HBV-DNA>105 copies/mL were treated with interferonalpha- 2b (PDferon: Pooyesh Darou, Tehran, Iran) for 52 weeks as 5 MU Sc. for 24 weeks in HBeAg(+) and 48 weeks for HBeAg(-) at baseline of study in Tehran, Iran. Serum HBV-DNA level using Cobas Amplicor HBV Monitor test and HBeAg status were assessed at baseline and end of 6-months follow-up. Sustained response (SR) (n=42, 56%) was defined by HBeAg seroconversion (n=12), or with a decrease in HBV-DNA >105 copies/mL to undetectable value (n=33), or chemical response (n=20).

Results: Higher pretreatment HBV-DNA levels have a significant relationship with better response to treatment in HBeAg (+) (R=0.7, p=0.04). Positivity of HBeAg in SR was a better predictor of chemical response in our patients, when compared to HBeAg negative (SR: 85% vs. 15%, respectively). At end of follow up, HBeAg (-) patients revealed more decrease in HBV-DNA levels than HBeAg (+) (412 vs. 290 105 copies/ml, p<0.05). Sensitivity of HBV-DNA in HBeAg (+) was more than HBeAg(-) (75% vs. 62%), but specificity was less in HBeAg(+) (58% vs. 45%). Area under ROC was 0.63 in HBeAg (-).

Conclusion: Higher pretreatment HBV-DNA levels have a significant relationship with better response to treatment in HBeAg positive patients of CHB. Although HBV-DNA in HBeAg negative was decreased significantly from baseline to end of follow-up, monitoring with sensitive quantitative baseline HBV-DNA measurement in these patients was not a better predictor of SR than HBeAg positive.

Keywords

Hepatitis B, Interferon-alpha-2b, Hepatitis B antigens

© 0, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: